Holen Sie sich die Stockscreener-App
2.105
1.20%
0.025
Handel nachbörslich:
2.10
-0.005
-0.24%
Schlusskurs vom Vortag:
$2.08
Offen:
$2.1
24-Stunden-Volumen:
5,348
Relative Volume:
0.13
Marktkapitalisierung:
$22.59M
Einnahmen:
$56.60M
Nettoeinkommen (Verlust:
$-34.12M
KGV:
-0.4592
EPS:
-4.5844
Netto-Cashflow:
$-1.36M
1W Leistung:
-6.03%
1M Leistung:
-3.88%
6M Leistung:
-18.09%
1J Leistung:
+6.85%
1-Tages-Spanne:
$2.09
$2.1705
1-Wochen-Bereich:
$2.08
$2.28
52-Wochen-Spanne:
$1.6501
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.105 | 23.61M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | Lake Street | Buy |
| 2025-06-30 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AYTU Maintained by Ascendiant Capital -- Price Target Raised to $14.50 - GuruFocus
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterUpward Estimate Revision - newsline.com
Aytu BioPharma Gains 5.89% as Small-Cap Biotech Finds TractionDaily Profile - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 3.3% as Shares Approach Resistance at $2.30Channel Breakout - newsline.com
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 - Hastings Tribune
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance ZoneSector ETF Flow - The Legal Advocate
AYTU Q1 2026 Earnings: EPS Misses Estimates by 1.88%, Stock Declines Amid Sparse DisclosureReturn On Assets - The Legal Advocate
AYTU: EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing - TradingView
AYTU Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesEarnings Trend Analysis - The Legal Advocate
AYTU Q1 2026 Earnings EPS Misses Estimates Amidst Operational ChallengesThe Legal Advocate - The Legal Advocate
Aytu BioPharma (AYTU) Holds Near Support Amid Low-Volume TradingWeak Sell Signals - newsline.com
Aytu BioPharma Rallies as Shares Test Key Resistance LevelsCumulative Volume - The Legal Advocate
Aytu BioPharma Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock MovementEarnings Call Highlights - The Legal Advocate
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Operational Challenges, Stock Rises SlightlyCFO Commentary Report - newsline.com
Aytu BioPharma Gains 1.64% as Stock Tests Key Resistance at $2.28ETF Flow - thelegaladvocate.com
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - ACCESS Newswire
Pharma firm Aytu BioPharma to present at virtual investor event May 28 - Stock Titan
Aytu outlines $6M-$7M quarterly sales and marketing spend range as EXXUA scripts rise to over 920 in April - MSN
Aytu BioPharma to Participate in September 2022 Investor Conferences - The Chronicle-Journal
Aytu BioPharma, Inc.Common Stock (NQ: AYTU - The Chronicle-Journal
What Aytu Bio AYTU is doing that separates it from the herd Institutional Selling 20260507Dividend Growth Analysis - The Legal Advocate
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Sahm
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2026 Earnings Call Transcript - Insider Monkey
AYTU BIOPHARMA INC | BIG RISK REWARD | AYTU STOCK | AYTU BIOPHARMA STOCK (K8VNph4cYO) - fathomjournal.org
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Stro - GuruFocus
Is Aytu BioPharma (AYTU) Overvalued After Q3 FY2026 Earnings Mis - GuruFocus
Aytu (AYTU) Reports Strong Q3 Revenue and Positive Launch Moment - GuruFocus
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
AYTU: EXXUA's launch drove strong early growth, with over 1,300 prescriptions and $2.4M in revenue - TradingView
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu (AYTU) Q3 2026 Earnings Transcript - The Globe and Mail
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call - Yahoo Finance
Aytu BioPharma (NASDAQ:AYTU) Surges 23% as EXXUA Launch Gains Early Traction in Mixed Q3 Results - ChartMill
Aytu BioPharma Q3 revenue falls amid EXXUA launch - TradingView
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results - ACCESS Newswire
AYTU BIOPHARMA Q3 EPS USD -0.53 - Moomoo
Aytu BioPharma (AYTU) swings to loss while launching EXXUA and cutting warrant liabilities - Stock Titan
EXXUA launch reshapes Aytu BioPharma (Nasdaq: AYTU) Q3 2026 results - Stock Titan
MSN Money - MSN
Aytu BioPharma Q3 Earnings Announcement Scheduled - Intellectia AI
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):